Thrombotic thrombocytopenic purpura historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Thrombotic thrombocytopenic purpura}}
{{Thrombotic thrombocytopenic purpura}}
{{CMG}}
{{CMG}} {{AE}} {{Saeedeh}}
==Overview==
==Overview==
==Historical Perspective==
==Historical Perspective==

Revision as of 18:39, 9 August 2018

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura historical perspective

CDC on Thrombotic thrombocytopenic purpura historical perspective

Thrombotic thrombocytopenic purpura historical perspective in the news

Blogs on Thrombotic thrombocytopenic purpura historical perspective

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saeedeh Kowsarnia M.D.[2]

Overview

Historical Perspective

  • In 1924, Eli Moschcowitz first describe TTP with a pentad of presentation.[1]
  • In 1960, plasma infusion was introduced as part of the treatment of a 8-year old patient with chronic anemia and thrombocytopenia by Schulman and colleagues [2].
  • In 1978, Upshaw first described the hereditary aspect of the disease which lacked and enzyme in the blood and responded to plasma transfusion .
  • Moschcowitz ascribed the disease (incorrectly) to a toxic cause. Moschcowitz noted that his 16 year-old patient had anemia; petechiae; microscopic hematuria; and at autopsy, disseminated microvascular thrombi. Since that time, the pathophysiology, etiology, and medical management of TTP has expanded.

References

  1. Moschcowitz E (1924). "An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease". Proc NY Pathol Soc. 24: 21–4. Reprinted in Mt Sinai J Med 2003;70(5):322-5, PMID 14631522.
  2. SCHULMAN I, PIERCE M, LUKENS A, CURRIMBHOY Z (1960). "Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency". Blood. 16: 943–57. PMID 14443744.

Template:WH Template:WS